Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

207 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
High non-compliance in the use of letrozole after 2.5 years of extended adjuvant endocrine therapy. Results from the IDEAL randomized trial.
Fontein DB, Nortier JW, Liefers GJ, Putter H, Meershoek-Klein Kranenbarg E, van den Bosch J, Maartense E, Rutgers EJ, van de Velde CJ. Fontein DB, et al. Among authors: nortier jw. Eur J Surg Oncol. 2012 Feb;38(2):110-7. doi: 10.1016/j.ejso.2011.11.010. Epub 2011 Dec 14. Eur J Surg Oncol. 2012. PMID: 22172646 Free article. Clinical Trial.
Quality of life in relation to tamoxifen or exemestane treatment in postmenopausal breast cancer patients: a Tamoxifen Exemestane Adjuvant Multinational (TEAM) Trial side study.
van Nes JG, Fontein DB, Hille ET, Voskuil DW, van Leeuwen FE, de Haes JC, Putter H, Seynaeve C, Nortier JW, van de Velde CJ. van Nes JG, et al. Among authors: nortier jw. Breast Cancer Res Treat. 2012 Jul;134(1):267-76. doi: 10.1007/s10549-012-2028-2. Epub 2012 Mar 28. Breast Cancer Res Treat. 2012. PMID: 22453754 Free PMC article. Clinical Trial.
Relationship between specific adverse events and efficacy of exemestane therapy in early postmenopausal breast cancer patients.
Fontein DBY, Houtsma D, Hille ETM, Seynaeve C, Putter H, Meershoek-Klein Kranenbarg E, Guchelaar HJ, Gelderblom H, Dirix LY, Paridaens R, Bartlett JMS, Nortier JWR, van de Velde CJH; Dutch TEAM Steering Committee. Fontein DBY, et al. Ann Oncol. 2012 Dec;23(12):3091-3097. doi: 10.1093/annonc/mds204. Epub 2012 Aug 2. Ann Oncol. 2012. PMID: 22865782 Free article.
Thyroid function alters during neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01).
de Groot S, Janssen LG, Charehbili A, Dijkgraaf EM, Smit VT, Kessels LW, van Bochove A, van Laarhoven HW, Meershoek-Klein Kranenbarg E, van Leeuwen-Stok AE, van de Velde CJ, Putter H, Nortier JW, van der Hoeven JJ, Pijl H, Kroep JR. de Groot S, et al. Among authors: nortier jw. Breast Cancer Res Treat. 2015 Jan;149(2):461-6. doi: 10.1007/s10549-014-3256-4. Epub 2015 Jan 4. Breast Cancer Res Treat. 2015. PMID: 25556355 Free PMC article. Clinical Trial.
Vitamin D (25-0H D3) status and pathological response to neoadjuvant chemotherapy in stage II/III breast cancer: Data from the NEOZOTAC trial (BOOG 10-01).
Charehbili A, Hamdy NA, Smit VT, Kessels L, van Bochove A, van Laarhoven HW, Putter H, Meershoek-Klein Kranenbarg E, van Leeuwen-Stok AE, van der Hoeven JJ, van de Velde CJ, Nortier JW, Kroep JR; Dutch Breast Cancer Research Group (BOOG). Charehbili A, et al. Among authors: nortier jw. Breast. 2016 Feb;25:69-74. doi: 10.1016/j.breast.2015.10.005. Epub 2015 Nov 21. Breast. 2016. PMID: 26614548 Clinical Trial.
207 results